Latigo Biotherapeutics, Inc. Closes $150 Million Series B Funding Round
Latigo Biotherapeutics, Inc., a U.S.-based biotechnology company specializing in the development of non-opioid pain therapies, has announced the closing of a $150 million Series B funding round. The round was led […]